Krishna Institute of Medical Sciences Limited CC-Mar25.pdf · 2025-05-13
Just another question on ARPOB. Probably you have answered this in some shape or form. But when you look at your ARPOB versus some of the other listed peers, I think at an overall company level, we are still trending much below. So it could be due to regional exposure, patient level mixes. But given that you're moving outside your core region now incrementally as well as improving patient level mix, from a 2- to 3-year perspective, do you think that this gap closes now?
Understood. That's fair. Any guidance you would like to share, though, for group level ARPOB because you're already at INR40,000, right? And incrementally, most of your regions or your expansion seem to be in higher ARPOB micro markets. So do you think that this INR40,000 could potentially trend higher towards INR50,000, INR75,000 over the next 2 to 3 years?